Grant of Stock Acquisition Rights to Directors, Executive Officers and Others
First written in FY2019-Q2. 3 of 6 entries say "Restated". Latest entry: FY2025.
- FY2025RestatedAnnual report
「Number of stock acquisition rights (rights) 430」
Stock acquisition rights equivalent to 43,000 shares in the First Series remain unexercised, unchanged from the end of the previous fiscal year. - FY2023RestatedAnnual report
「Outstanding unexercised 43,000」
Stock acquisition rights equivalent to 43,000 shares in the First Series remain unexercised, unchanged from the end of the previous fiscal year. - FY2022Additional forfeiture of stock acquisition rightsAnnual report
「After vesting (shares) End of previous consolidated fiscal year 48,000 Vesting — Exercise — Forfeiture 5,000 Outstanding unexercised 43,000」
An additional 5,000 shares' worth of the First Series of Stock Acquisition Rights was forfeited, reducing the outstanding unexercised amount from 48,000 shares to 43,000 shares. - FY2021Vesting and partial forfeiture of stock acquisition rightsAnnual report
「After vesting (shares) End of previous consolidated fiscal year — Vesting 50,000 Exercise — Forfeiture 2,000 Outstanding unexercised 48,000」
Of the First Series of Stock Acquisition Rights, rights equivalent to 50,000 shares vested, rights equivalent to 2,000 shares were forfeited, and 48,000 shares remained outstanding and unexercised. - FY2019RestatedAnnual report
「First Series of Stock Acquisition Rights (resolutions of the ordinary general meeting of shareholders on 27 September 2018 and the Board of Directors' meeting on 29 October 2018)」
The Company continues to disclose the terms of the First Series of Stock Acquisition Rights for directors, executive officers and subsidiary directors: 500 rights, 50,000 common shares, and an exercise period from 1 December 2020 to 30 November 2028. - FY2019-Q2First statedAnnual report
「First Series of Stock Acquisition Rights (resolutions of the ordinary general meeting of shareholders on 27 September 2018 and the Board of Directors' meeting on 29 October 2018)」
The Company issued 500 stock acquisition rights, equivalent to 50,000 common shares, with an exercise price of ¥26,200, to 4 Company directors, 2 Company executive officers and 4 directors of subsidiaries. The exercise period runs from 1 December 2020 to 30 November 2028.